Literature DB >> 14669792

Structural examination of tryptase- and chymase-positive mast cells in livers, containing metastases from gastrointestinal cancers.

Maya Vladova Gulubova1.   

Abstract

Human mast cells are categorized into mast cells positive only for tryptase (MC(T)) and mast cells positive for both tryptase and chymase (MC(TC)). The structural appearance of tryptase-, and chymase-positive mast cells in metastatic liver disease and the variations in MC(T) and MC(TC) numbers in accordance with the origin of the primary tumors have been described in the present study. Liver mast cells are analyzed immunocytochemically using tryptase and chymase and by quantitative morphometry in 30 patients with colorectal (n = 15), gastric (n = 8), and pancreatic (n = 7) cancers and in 5 control livers. The numbers of MC(T) and MC(TC) are increased in the extratumoral liver tissue (mainly portal tracts) as compared to controls. The numbers of MC(T) and MC(TC) in and around metastases with moderate or high grade of differentiation are statistically significantly higher, as compared to those with low grades of differentiation. The numbers of MC(TC) are greater than that of MC(T) in the extratumoral liver tissue and in metastases themselves. Ultrastructurally, mast cells immunostained with tryptase and chymase have three types of granules: electron dense granules with darkly precipitated reaction product, electron lucent granules without reaction product and electron lucent granules with sparse reaction product (altered granules). Both types of mast cells have small and large in size granules, resembling the MC(TC) phenotype described earlier. Tryptase-positive mast cells have granules with discrete scrolls and particulate and beaded pattern. Chymase-positive mast cells have granules with finely granular or particulate material. Substance P (SP)- and vasointestinal polypeptide (VIP)-positive mast cells are not observed in livers with metastases. The present study suggests that liver mast cells are mainly from the MC(TC) type, and are accumulated in peritumoral and metastatic areas. They may play a role in the formation of tumor stroma, or in tumor immunology in liver metastases from various primary gastrointestinal cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669792     DOI: 10.1023/a:1027310827655

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue.

Authors:  H J Nielsen; U Hansen; I J Christensen; C M Reimert; N Brünner; F Moesgaard
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

2.  Migration of neutrophils is dependent on mast cells in nonspecific pleurisy in rats.

Authors:  M Nishida; R Uchikawa; T Tegoshi; M Yamada; S Matsuda; Y Hyoh; N Arizono
Journal:  APMIS       Date:  1999-10       Impact factor: 3.205

3.  The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus.

Authors:  G O Elpek; T Gelen; N H Aksoy; A Erdoğan; L Dertsiz; A Demircan; N Keleş
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  T Terada; Y Matsunaga
Journal:  J Hepatol       Date:  2000-12       Impact factor: 25.083

5.  The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix.

Authors:  L Benítez-Bribiesca; A Wong; D Utrera; E Castellanos
Journal:  J Histochem Cytochem       Date:  2001-08       Impact factor: 2.479

6.  Stem cell factor expressed in human gastric mucosa in relation to mast cell increase in Helicobacter pylori-infected gastritis.

Authors:  Nobumichi Bamba; Shigemi Nakajima; Akira Andoh; Masamichi Bamba; Hiroyuki Sugihara; Tadao Bamba; Takanori Hattori
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

7.  Mast cell-fibroblast interactions: human mast cells as source and inducers of fibroblast and epithelial growth factors.

Authors:  Metin Artuc; U Muscha Steckelings; Beate M Henz
Journal:  J Invest Dermatol       Date:  2002-03       Impact factor: 8.551

8.  Volume-corrected mitotic index in human pancreatic cancer. Relation to histologic grade, clinical stage, and prognosis.

Authors:  P K Lipponen; M J Eskelinen; Y Collan; S Marin; E Alhava
Journal:  Scand J Gastroenterol       Date:  1990-06       Impact factor: 2.423

9.  Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study.

Authors:  M Yamashiro; W Kouda; N Kono; K Tsuneyama; O Matsui; Y Nakanuma
Journal:  Virchows Arch       Date:  1998-11       Impact factor: 4.064

10.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms.

Authors:  H Haapasalo; E Pesonen; Y Collan
Journal:  Pathol Res Pract       Date:  1989-11       Impact factor: 3.250

View more
  4 in total

1.  Immunosurveillance function of human mast cell?

Authors:  Oner Ozdemir
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 2.  The emerging role of mast cells in liver disease.

Authors:  Veronica Jarido; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Kristen Stephenson; Heather Francis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-04       Impact factor: 4.052

Review 3.  Pre-Cancerous Lesions in the Oral and Maxillofacial Region: A Literature Review with Special Focus on Etiopathogenesis.

Authors:  Soussan Irani
Journal:  Iran J Pathol       Date:  2016

4.  Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients.

Authors:  Francielle Beltrão Pereira; Walderez O Dutra; Kenneth J Gollob; Edna Afonso Reis; Ana Laura Grossi de Oliveira; Manoel Otávio da Costa Rocha; Cristiane Alves da Silva Menezes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-10-22       Impact factor: 1.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.